Clinical Trial Update: Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effect of dapagliflozin on progression from prediabetes to type 2 diabetes in subjects with myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Myocardial Infarction
• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: PreDiabetes, Myocardial Infarction | Phase 3 | Status: UNKNOWN